Open application window

Coccidioidomycosis Collaborative Research Centers (P01 Clinical Trial Not Allowed) deadline 2026

The current listed application deadline is July 8, 2026. Use this page to verify timing fast, then move into the full grant record for planning, comparison, and drafting.

Agency
National Institutes of Health
Award range
Up to $1,200,000
Total funding
$4,800,000
Funding instrument
Grant
CFDA / ALN
93.855
Cost share
No

Application Countdown

58
Days
11
Hours
46
Minutes

Use this page as the fast check for timing, then jump into the full grant record for filters, drafting, and comparison.

Quick facts

Opportunity number
Not listed
Last updated
May 3, 2026
Expected awards
4

Deadline summary

The purpose of the notice of funding opportunity (NOFO) is to solicit applications for a Coccidioidomycosis Collaborative Research Centers (CCRC) program. This new initiative will establish highly collaborative, multi-disciplinary, research teams to conduct translational and clinical research to support the development of a Valley fever vaccine as outlined in NIAID's Strategic Plan for Research to Develop a Valley fever Vaccine.

Key dates

Posted
May 3, 2026
Deadline
July 8, 2026

Before you apply

Confirm the official submission path and any portal requirements.
Review the close date carefully and account for agency timezone handling.
Validate fit against the listed eligibility groups before investing drafting time.
This program expects about 4 awards, which can help frame competitiveness.

Eligibility snapshot

State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher education

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.